No decline in cognition scores in patients with mild alzheimer's disease who received simufilam continuously for 24 months

Austin, texas, feb. 07, 2024 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a biotechnology company, today reported top-line results of a two-year clinical safety study of simufilam, an investigational oral drug for the proposed treatment of alzheimer's disease dementia. the study enrolled over 200 patients with mild to moderate alzheimer's and consisted of two open-label treatment phases and a randomized, placebo-controlled withdrawal phase. average changes in adas-cog scores, baseline to month 24, indicate the following:
SAVA Ratings Summary
SAVA Quant Ranking